Regardless of diabetic status, worse ischemic outcomes were observed in patients undergoing percutaneous coronary intervention (PCI) with high levels of high sensitivity C-reactive protein (hsCRP) (defined as >3 mg/L).

• In this study of 11,979 participants, the prognostic value of hsCRP levels was assessed in diabetic and nondiabetic patients undergoing PCI.

• Among nondiabetics and diabetics, 24.7% and 29.8% of patients, respectively, had high hsCRP levels.

• Elevated rates of major adverse cardiovascular events were found in both diabetics and nondiabetics with high hsCRP levels, vs their counterparts with low hsCRP, primarily driven by elevated rates all cause deaths.

• Only in diabetics, increased rates of target vessel revascularization and myocardial infarction were observed in relation to high hsCRP levels, but there was no significant interaction between inflammation and diabetes.